JP2017537158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537158A5 JP2017537158A5 JP2017548325A JP2017548325A JP2017537158A5 JP 2017537158 A5 JP2017537158 A5 JP 2017537158A5 JP 2017548325 A JP2017548325 A JP 2017548325A JP 2017548325 A JP2017548325 A JP 2017548325A JP 2017537158 A5 JP2017537158 A5 JP 2017537158A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- thiazolo
- tetrahydrofuran
- hydroxy
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/093224 | 2014-12-08 | ||
| CN2014093224 | 2014-12-08 | ||
| CNPCT/CN2015/086987 | 2015-08-14 | ||
| CN2015086987 | 2015-08-14 | ||
| PCT/EP2015/078439 WO2016091698A1 (en) | 2014-12-08 | 2015-12-03 | 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537158A JP2017537158A (ja) | 2017-12-14 |
| JP2017537158A5 true JP2017537158A5 (OSRAM) | 2020-04-30 |
| JP6817217B2 JP6817217B2 (ja) | 2021-01-20 |
Family
ID=54771116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548325A Active JP6817217B2 (ja) | 2014-12-08 | 2015-12-03 | ウイルス感染症の治療および予防のための３−置換された５−アミノ−６Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２，７−ジオン化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9441008B2 (OSRAM) |
| EP (1) | EP3230298B1 (OSRAM) |
| JP (1) | JP6817217B2 (OSRAM) |
| KR (2) | KR20230113824A (OSRAM) |
| CN (2) | CN106164079B (OSRAM) |
| AU (1) | AU2015359692B2 (OSRAM) |
| BR (1) | BR112017011941B1 (OSRAM) |
| CA (1) | CA2963717C (OSRAM) |
| CL (1) | CL2017001426A1 (OSRAM) |
| CR (1) | CR20170237A (OSRAM) |
| DK (1) | DK3230298T3 (OSRAM) |
| EA (1) | EA038744B1 (OSRAM) |
| ES (1) | ES2864223T3 (OSRAM) |
| HR (1) | HRP20210454T1 (OSRAM) |
| HU (1) | HUE053704T2 (OSRAM) |
| IL (1) | IL251285B (OSRAM) |
| LT (1) | LT3230298T (OSRAM) |
| MA (1) | MA41134B1 (OSRAM) |
| MX (1) | MX379474B (OSRAM) |
| MY (1) | MY194002A (OSRAM) |
| PE (1) | PE20170679A1 (OSRAM) |
| PH (1) | PH12017501061B1 (OSRAM) |
| PL (1) | PL3230298T3 (OSRAM) |
| PT (1) | PT3230298T (OSRAM) |
| RS (1) | RS61612B1 (OSRAM) |
| SG (1) | SG11201704512PA (OSRAM) |
| SI (1) | SI3230298T1 (OSRAM) |
| TW (1) | TWI733656B (OSRAM) |
| UA (1) | UA124184C2 (OSRAM) |
| WO (1) | WO2016091698A1 (OSRAM) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3230298T1 (sl) * | 2014-12-08 | 2021-04-30 | F. Hoffmann-La Roche Ag | Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom |
| HRP20200943T1 (hr) * | 2015-03-16 | 2020-09-18 | F. Hoffmann - La Roche Ag | Kombinirani tretman s agonistom tlr7 i inhibitorom hbv kapside |
| CN107592864B (zh) | 2015-05-12 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 |
| JP6839104B2 (ja) * | 2015-06-30 | 2021-03-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| WO2018127525A1 (en) * | 2017-01-06 | 2018-07-12 | F. Hoffmann-La Roche Ag | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS |
| CN110167947B (zh) | 2017-01-06 | 2022-05-03 | 豪夫迈·罗氏有限公司 | 乙酸[(1S)-1-[(2S,4R,5R)-5-(5-氨基-2-氧代-噻唑并[4,5-d]嘧啶-3-基)-4-羟基-四氢呋喃-2-基]丙基]酯的固体形式 |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| JP2021506827A (ja) | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | 肝炎の治療用の抗体コンストラクト−薬物コンジュゲート |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| JP7423085B2 (ja) | 2018-05-25 | 2024-01-29 | プリミューン・セラピューティクス・インコーポレイテッド | Ｔｌｒ７アゴニスト |
| MX2021000404A (es) | 2018-07-13 | 2021-03-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de rtel1. |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2020257407A1 (en) | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| PE20221324A1 (es) | 2019-11-26 | 2022-09-09 | Primmune Therapeutics Inc | Agonistas del tlr7 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| CN114828852A (zh) | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| KR20220119616A (ko) | 2019-12-24 | 2022-08-30 | 에프. 호프만-라 로슈 아게 | Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법 |
| CA3163490A1 (en) | 2019-12-24 | 2021-07-01 | F. Hoffman-La Roche Ag | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2022031021A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신 |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| CN118284695A (zh) | 2021-11-11 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的药物组合 |
| WO2025032082A1 (en) * | 2023-08-08 | 2025-02-13 | F. Hoffmann-La Roche Ag | Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
| US5041426A (en) * | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| EP1072607A3 (en) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses therof |
| JP2001524936A (ja) | 1996-10-16 | 2001-12-04 | アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド | プリンｌ―ヌクレオシド類およびその用途 |
| US20050004144A1 (en) | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| US7576068B2 (en) | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
| CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| US7560544B2 (en) * | 2004-12-17 | 2009-07-14 | Anadys Pharmaceuticals, Inc. | 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof |
| AU2006318260B2 (en) | 2005-11-21 | 2012-05-17 | Anadys Pharmaceuticals, Inc. | Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one |
| CL2007001427A1 (es) | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
| TWI418561B (zh) * | 2006-06-22 | 2013-12-11 | Anadys Pharmaceuticals Inc | ５-胺基-３-（３’-去氧-β-Ｄ-核糖呋喃糖基（ｒｉｂｏｆｕｒａｎｏｓｙｌ））-噻唑并〔４，５-ｄ〕嘧啶-２，７-二酮之前藥 |
| US7528115B2 (en) | 2006-07-18 | 2009-05-05 | Anadys Pharmaceuticals, Inc. | Carbonate and carbamate prodrugs of thiazolo[4,5-d]pyrimidines |
| BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
| WO2009026292A1 (en) * | 2007-08-20 | 2009-02-26 | Anadys Pharmaceuticals, Inc. | Dosing methods for treating disease |
| SI3230298T1 (sl) | 2014-12-08 | 2021-04-30 | F. Hoffmann-La Roche Ag | Spojine 3-substituiranega 5-amino-6H-tiazolo(4,5-d)pirimidin-2,7-diona za zdravljenje ali preprečevanje okužbe z virusom |
| HRP20200943T1 (hr) | 2015-03-16 | 2020-09-18 | F. Hoffmann - La Roche Ag | Kombinirani tretman s agonistom tlr7 i inhibitorom hbv kapside |
| CN107592864B (zh) | 2015-05-12 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的取代的氨基噻唑并嘧啶二酮 |
| JP6839104B2 (ja) | 2015-06-30 | 2021-03-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ウイルス感染の治療及び予防のための新規な置換アミノチアゾロピリミジンジオン |
-
2015
- 2015-12-03 SI SI201531553T patent/SI3230298T1/sl unknown
- 2015-12-03 MY MYPI2017702051A patent/MY194002A/en unknown
- 2015-12-03 AU AU2015359692A patent/AU2015359692B2/en active Active
- 2015-12-03 RS RS20210297A patent/RS61612B1/sr unknown
- 2015-12-03 CA CA2963717A patent/CA2963717C/en active Active
- 2015-12-03 DK DK15804128.5T patent/DK3230298T3/da active
- 2015-12-03 EA EA201791011A patent/EA038744B1/ru unknown
- 2015-12-03 PT PT158041285T patent/PT3230298T/pt unknown
- 2015-12-03 EP EP15804128.5A patent/EP3230298B1/en active Active
- 2015-12-03 HU HUE15804128A patent/HUE053704T2/hu unknown
- 2015-12-03 CN CN201580018026.1A patent/CN106164079B/zh active Active
- 2015-12-03 US US14/958,619 patent/US9441008B2/en active Active
- 2015-12-03 ES ES15804128T patent/ES2864223T3/es active Active
- 2015-12-03 LT LTEP15804128.5T patent/LT3230298T/lt unknown
- 2015-12-03 PL PL15804128T patent/PL3230298T3/pl unknown
- 2015-12-03 UA UAA201706823A patent/UA124184C2/uk unknown
- 2015-12-03 WO PCT/EP2015/078439 patent/WO2016091698A1/en not_active Ceased
- 2015-12-03 PE PE2017000551A patent/PE20170679A1/es unknown
- 2015-12-03 CN CN201710845723.5A patent/CN107445980B/zh active Active
- 2015-12-03 BR BR112017011941-2A patent/BR112017011941B1/pt active IP Right Grant
- 2015-12-03 MX MX2017007044A patent/MX379474B/es unknown
- 2015-12-03 MA MA41134A patent/MA41134B1/fr unknown
- 2015-12-03 KR KR1020237024143A patent/KR20230113824A/ko not_active Ceased
- 2015-12-03 SG SG11201704512PA patent/SG11201704512PA/en unknown
- 2015-12-03 HR HRP20210454TT patent/HRP20210454T1/hr unknown
- 2015-12-03 JP JP2017548325A patent/JP6817217B2/ja active Active
- 2015-12-03 KR KR1020177015128A patent/KR102557560B1/ko active Active
- 2015-12-03 CR CR20170237A patent/CR20170237A/es unknown
- 2015-12-07 TW TW104140978A patent/TWI733656B/zh active
-
2016
- 2016-07-11 US US15/207,338 patent/US10040815B2/en active Active
-
2017
- 2017-03-20 IL IL251285A patent/IL251285B/en unknown
- 2017-06-05 CL CL2017001426A patent/CL2017001426A1/es unknown
- 2017-06-07 PH PH12017501061A patent/PH12017501061B1/en unknown
-
2018
- 2018-07-02 US US16/025,170 patent/US10618929B2/en active Active
-
2020
- 2020-04-13 US US16/847,552 patent/US11180525B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537158A5 (OSRAM) | ||
| JP2013508279A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2020040972A (ja) | テノホビルアラフェナミドヘミフマレート | |
| JP2020512337A5 (OSRAM) | ||
| JP2009535352A5 (OSRAM) | ||
| JP2017531038A5 (OSRAM) | ||
| JP2008523098A5 (OSRAM) | ||
| JP2009523760A5 (OSRAM) | ||
| JP2009502743A5 (OSRAM) | ||
| HRP20210454T1 (hr) | 3-supstituirani 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-dion spojevi za liječenje i profilaksu virusne infekcije | |
| JP2005523922A5 (OSRAM) | ||
| JP2005519916A5 (OSRAM) | ||
| WO2022174194A1 (en) | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2010077141A5 (OSRAM) | ||
| JP2010514758A5 (OSRAM) | ||
| JP2020514316A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2019500387A5 (OSRAM) | ||
| CN114867351B (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| JP2011507896A5 (OSRAM) | ||
| JP2017512211A5 (OSRAM) | ||
| JP2020511536A5 (OSRAM) | ||
| JP2010500284A5 (OSRAM) | ||
| JP2004525183A5 (OSRAM) |